Long-Term Complete Remission of a Patient With Double-Hit Diffuse Large B-Cell Lymphoma Treated by Chemoimmunotherapy and Chinese Herbal Medicine

被引:2
|
作者
Liang, Henry [1 ,4 ]
Guo, Jessica [2 ]
Li, Chun Guang [3 ]
机构
[1] Western Sydney Univ, Campbelltown Campus, Artarmon, NSW, Australia
[2] Dr Henry Liang Clin, Artarmon, NSW, Australia
[3] Western Sydney Univ, NICM Hlth Res Inst, Penrith, NSW, Australia
[4] Dr Henry Liang Clin, Level 1, 66 Hampden Rd, Artarmon, NSW 2064, Australia
关键词
diffuse large B-cell lymphoma; double-hit lymphoma; complete remission; long term survival; Chinese herbal medicine; MULTICENTER;
D O I
10.1177/15347354221147515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Double-hit diffuse large B-cell lymphoma (DHL) is an uncommon subtype of lymphoma which poorly responds to current drug therapies and has low rates of long-term survival in the patients. Herein, we report a case of a 73-year-old Caucasian male who was diagnosed with DHL with double-hit mutations of rearrangement of both c-MYC and BCL2 in November 2013. He commenced the standard R-CHOP-14 chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) but changed to dose-adjusted DA-EPOCH-R protocol (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and rituximab) in the second and third cycles due to double-hit mutation. Because of intolerance to the intensive therapy, the patient decided to switch to Chinese medicine intervention. From March 2014 to December 2019, he was prescribed with a classical Chinese herbal formula-Sijunzi Decoction plus Prunella vulgaris based prescriptions. After 2 months of the Chinese herbal medicine intervention, the patient felt his right groin mass disappeared. Imaging follow-up showed no residual masses, and no lymphadenopathy was seen. During the period of Chinese herbal medicine treatment, his adherence and tolerability were well maintained with no adverse events. Imaging surveillances afterward found no evidence of lymphoma recurrence. His regular blood tests indicated that the patient's blood counts were normal and stable; no hematologic toxicity, hepatoxicity, or nephrotoxicity associated with Chinese herbal medicine were found. Follow-up visits until 2020 found that he had been living and enjoying a good quality of life for over 8 years post-diagnosis. This case study illustrates the potential values of Chinese herbal medicine in DHL treatment, alongside chemo-immunotherapy, and in maintaining long-term survival and satisfactory quality of life for DHL patients. The case report provides clinicians with preliminary evidence of the use of Chinese herbal medicine as a therapeutic strategy in the management of DHL.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone
    Cencini, Emanuele
    Rocco, Melania
    Ghio, Francesco
    Simonetti, Federico
    Cuccaro, Annarosa
    De Marco, Federica
    Consoli, Chiara
    Bocchia, Monica
    Fabbri, Alberto
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (02) : 247 - 253
  • [32] Primary Mediastinal Large B-Cell Lymphoma With Translocations Involving BCL6 and MYC (Double-Hit Lymphoma)
    Campuzano-Zuluaga, German
    Ortiz, Daniel
    Peng, Jing-Hong
    Ikpatt, Offiong Francis
    Fan, Yao-Shan
    Barredo, Julio C.
    Vega, Francisco
    Chapman, Jennifer R.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 145 (05) : 710 - 716
  • [33] Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Upper Limb: Double Hit/Double Expressor with CNS Involvement: From Hospice to Remission
    Castillo, Brenda S.
    Rodriguez, Maria L.
    Chao, Ju-Hsien John
    Zoghi, Behyar
    CASE REPORTS IN HEMATOLOGY, 2019, 2019
  • [34] Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab
    Kobayashi, Tsutomu
    Tsutsumi, Yasuhiko
    Sakamoto, Natsumi
    Nagoshi, Hisao
    Yamamoto-Sugitani, Mio
    Shimura, Yuji
    Mizutani, Shinsuke
    Matsumoto, Yosuke
    Nishida, Kazuhiro
    Horiike, Shigeo
    Asano, Naoko
    Nakamura, Shigeo
    Kuroda, Junya
    Taniwaki, Masafumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (11) : 1035 - 1042
  • [35] COMPLETE REMISSION FOLLOWING RECOMBINANT INTERFERON-ALPHA-2A IN A PATIENT WITH DIFFUSE LARGE B-CELL CUTANEOUS LYMPHOMA
    TOURANI, JM
    LEAUTE, JB
    LESSANALEIBOWITCH, M
    ANDRIEU, JM
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1989, 31 (04): : 315 - 316
  • [36] Primary splenic diffuse large B-cell lymphoma double hit: A subtype of poor prognosis
    Martinez Manzano, Alvaro
    Balsalobre Salmeron, Maria Dolores
    Garcia Lopez, Maria Aranzazu
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (04): : 143 - 145
  • [37] Triple-Hit B-Cell Lymphoma: Case Report of an Elderly Patient Achieving Complete Remission
    Annunziata, Joseph
    Balog, Anna
    Tang, Bang
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 : S78 - S78
  • [38] 'Double-hit' lymphomas with BCL-2 and MYC translocations in patients with diffuse large B-cell lymphoma diagnosed in 2009 at Herlev Hospital
    Pedersen, M. O.
    Gang, A. O.
    Poulsen, T. S.
    Knudsen, H.
    Falensteen, A.
    Talmann, M. L. M.
    Nielsen, S. L.
    Norgaard, P.
    APMIS, 2010, 118 : 22 - 22
  • [39] Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation
    Ganesan, P.
    Sagar, T. G.
    Kannan, K.
    Radhakrishnan, V
    Rajaraman, S.
    John, A.
    Sundersingh, S.
    Mahajan, V
    Ganesan, T. S.
    INDIAN JOURNAL OF CANCER, 2017, 54 (02) : 430 - 435
  • [40] Long-term clinical course of immunotactoid glomerulopathy complicated with diffuse large B-cell lymphoma
    Takahashi, Haruka
    Sano, Takashi
    Kawamura, Sayumi
    Sano, Keiko
    Miyasaka, Ryoma
    Yamazaki, Takuya
    Sakakibara, Mayuko
    Abe, Tetsuya
    Hashimoto, Keiko
    Nagaoka, Miki
    Kamata, Mariko
    Naito, Shokichi
    Aoyama, Togo
    Moriya, Rika
    Takeuchi, Yasuo
    CEN CASE REPORTS, 2022, 11 (02) : 184 - 190